Janet Dillione, a director at CorMedix Inc, sold 10,000 shares in late January 2026, executing transactions between $6.85 and $6.90 per share, totaling $68,800. Post-sale, Dillione retains direct ownership of 38,473 shares. The company disclosed preliminary Q4 2025 net revenue of approximately $127 million, with 2025 fullyear revenue at $310 million. Including the Melinta acquisition, pro forma 2025 revenue reached about $400 million. For fiscal 2026, CorMedix projected revenues between $300 million and $320 million, reflecting a decline versus pro forma 2025 figures. This forecast factored in $150 million to $170 million attributed to its DefenCath product. Market analysts have responded with downward price target adjustments but maintained positive ratings. Concurrently, CorMedix announced important leadership changes with the CEO assuming the Chairman role and a new executive appointed as EVP and Chief Commercial Officer.
Key Points
- Director Janet Dillione sold 10,000 shares at an average price between $6.85 and $6.90, totaling $68,800, and now directly holds 38,473 shares.
- CorMedix reported preliminary Q4 2025 net revenue of approximately $127 million and full-year 2025 revenue of $310 million; pro forma revenue including the Melinta acquisition reached about $400 million in 2025.
- Fiscal 2026 revenue guidance is set between $300 million and $320 million, indicating a decrease from pro forma 2025 figures; DefenCath product revenues expected at $150 million to $170 million.
- Analysts have lowered price targets but maintain positive ratings due to revenue guidance falling short of Street expectations; leadership changes include CEO becoming Chairman and new EVP/CCO appointment.
Janet Dillione, serving as a director of CorMedix Inc (NASDAQ: CRMD), completed a sale of 10,000 shares of the company's common stock on January 21, 2026. According to a filing with the Securities and Exchange Commission, the shares were sold at a weighted average price ranging from $6.85 to $6.90 per share, yielding a total transaction value of $68,800. Following this transaction, Dillione retains ownership of 38,473 shares in CorMedix.
CorMedix has recently provided preliminary, unaudited financial results for the fourth quarter of 2025, reporting net revenues near $127 million. The full-year revenue for 2025 stood at approximately $310 million. When accounting for the Melinta acquisition on a pro forma basis, assuming the acquisition was effective from January 1, 2025, the company’s net revenue for 2025 is estimated to be around $400 million.
Looking forward, CorMedix issued guidance for the 2026 fiscal year with expected revenues projected between $300 million and $320 million. This outlook would mark a decrease compared to the company’s pro forma 2025 revenue. Within this forecast, revenues from the DefenCath product are anticipated to range from $150 million to $170 million.
In reaction to the revenue guidance, several market analysts have adjusted their valuations of CorMedix stock. Truist Securities lowered its price target from $20.00 to $16.00, yet retained a Buy rating, citing the 2026 revenue guidance as approximately 40% below consensus forecasts. Similarly, Leerink Partners reduced its price target from $21.00 to $15.00 while maintaining an Outperform rating, basing this on the long-term revenue prospects of the DefenCath product.
Alongside financial updates, CorMedix announced recent leadership transitions. CEO Joseph Todisco has taken on the additional role as Chairman of the Board, and Mike Seckler has joined the company as Executive Vice President and Chief Commercial Officer. These changes signify a strategic realignment within the company's executive structure.
This development comes during a period of scrutiny on CorMedix’s revenue trajectory and market performance. The company’s revised forecast and executive moves are elements investors and analysts will likely watch closely as they assess shareholder value and strategic execution in the coming months.
Risks
- Fiscal 2026 revenue forecast is substantially lower than the pro forma 2025 revenue, presenting uncertainty around growth trajectory and revenue sustainability, impacting investors and biotech market sentiment.
- Market analysts' downward revisions in price targets reflect concerns about the company’s short-term prospects and valuation, highlighting risks for shareholders in the healthcare sector.
- Leadership transitions, although not explicitly negative, present an element of operational uncertainty amid ongoing revenue adjustments, potentially affecting strategic consistency.
More from Insider Trading
